Welcome to our dedicated page for Nukkleus SEC filings (Ticker: NUKK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nukkleus Inc. (NASDAQ: NUKK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Nukkleus structures and finances its acquisitions, manages its capital, and consolidates its growing portfolio of defense, aerospace, and advanced manufacturing businesses.
Through current reports on Form 8‑K, Nukkleus details material events such as the completion of its acquisition of Tiltan Software Engineering Ltd., including the purchase price structure, secured promissory note, escrowed common stock, and pledge of the acquired shares. Other 8‑K filings describe shareholder approvals for the acquisition of Star 26 Capital Inc., the issuance of common stock and warrants, and the establishment of a $250 million equity line. Additional 8‑Ks cover the pricing and closing of SC II Acquisition Corp.’s SPAC IPO, where an indirect Nukkleus subsidiary acts as sponsor and Nukkleus’ CEO serves as SC II’s chief executive officer.
Nukkleus’ registration statements on Form S‑1 provide further detail on its capital structure. One S‑1 explains the resale registration of shares issuable upon conversion of Series A Convertible Preferred Stock and the exercise of common stock purchase warrants issued in a private placement. Another S‑1 describes the committed equity financing arrangement with Esousa Group Holdings, LLC, including the mechanics of selling common stock over time under the Common Stock Purchase Agreement and the associated commitment shares.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as conversion prices, warrant exercise mechanics, voting results from special and annual meetings, and conditions related to Nasdaq Listing Rules. Users can quickly see how Nukkleus reports acquisitions like Tiltan and Star 26, how it discloses direct financial obligations and pledge agreements, and how equity-linked instruments may affect future common stock issuance. The filings page also provides a structured view of proxy statements, including the DEF 14A describing the Star 26 transaction and related share issuance proposals.
For investors tracking insider and ownership-related information, the NUKK filings set out voting outcomes, equity incentive plan approvals, and the roles of key shareholders and affiliates in transactions such as the Star 26 acquisition and the SC II sponsorship. By combining real-time EDGAR updates with AI explanations, the NUKK SEC filings page helps readers interpret complex legal and financial disclosures in the context of Nukkleus’ broader aerospace and defense acquisition strategy.
Nukkleus Inc. (NUKK) filed a current report to note that on November 25, 2025 it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The filing does not describe the contents of the press release, only that it has been formally released and furnished to the market.
The report also reiterates that Nukkleus’s common stock trades on Nasdaq under the symbol NUKK, and its publicly listed warrants, each exercisable for one share of common stock at $92.00 per share, trade under the symbol NUKKW.
Nukkleus Inc. has filed a Form S-8 to register 3,890,000 shares of its common stock, par value $0.0001 per share, tied to its 2025 Equity Incentive Plan. This includes 855,000 shares reserved for future awards under the plan and 3,035,000 shares already issued to employees, directors, officers and consultants that may be resold by the selling stockholders using this reoffer prospectus. Nukkleus will only receive limited cash proceeds if stock options are exercised for cash; it will not receive proceeds from resale of shares by the selling stockholders.
The selling stockholders may dispose of their shares over time through various methods, including ordinary brokerage trades, block trades, privately negotiated transactions, exchange distributions and short sales entered into after the registration statement is declared effective. Nukkleus’s common stock trades on the Nasdaq Capital Market under the symbol “NUKK”, and the closing price on November 21, 2025 was $4.32 per share.
Nukkleus Inc. filed a current report to note that it issued a press release on November 25, 2025, which is attached as Exhibit 99.1. The report classifies this under an "Other Events" section, meaning the company is formally making investors aware of information contained in that press release.
The filing also lists Nukkleus’ securities that trade on The Nasdaq Global Market, including its common stock under the symbol NUKK and warrants under NUKKW, each exercisable for one share of common stock at $92.00 per share. The company states that the press release and related exhibit are being furnished rather than filed, which affects how they are treated under securities law liability provisions.
Nukkleus Inc. is asking stockholders to approve several major share issuance proposals tied to a transformational acquisition and new financing tools. The centerpiece is the Star Agreement, under which Nukkleus would acquire 100% of Star 26 Capital for consideration including $21,000,000 (a $16,000,000 12‑month note and $5,000,000 cash, less prior loans), 4,770,340 shares of common stock, a five‑year warrant for 12,017,648 shares at $1.50, an additional $3,000,000 in cash and a $3,000,000 six‑month note at 8% interest.
At the record date there were 16,645,766 common shares outstanding; the Star equity holders would own 28.7% of these shares after closing and could hold 50.2% of the post‑transaction shares if they fully exercise the Star Warrant. Other proposals seek approval for the exercise of existing warrants for 3,191,400 shares at $5.405, for issuing shares above Nasdaq’s 20% cap under a $250,000,000 equity line of credit with Esousa, and for issuing shares above a similar cap upon conversion of Series A preferred stock initially convertible into 2,044,800 common shares.
Nukkleus Inc. (NUKK) reported an insider equity award on Form 4. A company director received 5,000 shares of common stock on 11/13/2025. The shares, with a stated price of $0 per share, were issued under the company’s 2025 Equity Incentive Plan as consideration for services rendered to Nukkleus Inc.
Following this grant, the reporting person beneficially owns 15,000 shares of Nukkleus common stock in direct ownership. The filing is made by a single reporting person in their capacity as a director of the company.
Nukkleus Inc. (NUKK) reported that a company director acquired additional common stock through an equity award. On 11/13/2025, the reporting person received 10,000 shares of Nukkleus common stock at a price of $0 per share under the company’s 2025 Equity Incentive Plan in consideration of services rendered to the company. After this transaction, the director beneficially owns 20,000 shares of Nukkleus common stock held directly.
Nukkleus Inc. (NUKK) reported an insider equity grant on a Form 4. A director received 5,000 shares of common stock on 11/13/2025 under the company’s 2025 Equity Incentive Plan as consideration for services to the company. The transaction was recorded at a price of $0.00 per share, reflecting a stock award rather than an open-market purchase. Following this grant, the director now beneficially owns 15,000 shares of Nukkleus common stock in direct ownership.
Nukkleus Inc. (NUKK) reported a director equity award on a Form 4. On 11/13/2025, the reporting person, serving as a director, acquired 5,000 shares of common stock at a price of $0. The filing explains that these shares were issued under the company's 2025 Equity Incentive Plan in consideration for services provided to the company. Following this transaction, the reporting person beneficially owned 15,000 shares of Nukkleus common stock, held directly.
Nukkleus Inc. (NUKK) reported an insider equity award to its Chief Executive Officer and director, Menachem Shalom. On 11/13/2025, he acquired 750,000 shares of Nukkleus common stock at a stated price of $0.00 per share. After this grant, he beneficially owns 1,250,000 shares of common stock in direct ownership. The filing explains that these shares were issued under the company’s 2025 Equity Incentive Plan as consideration for services rendered to Nukkleus.
Nukkleus Inc. reported net income of $89.6 million for the nine months ended September 30, 2025, up from $0.4 million a year earlier, mainly due to a non-cash gain of $123.4 million from changes in the fair value of warrant liabilities and a $2.5 million gain on deconsolidating a discontinued subsidiary. The core business generated no revenue and incurred $7.3 million of operating expenses, resulting in an operating loss from continuing operations.
Cash was $7.6 million with a working capital deficit of about $30.5 million and a stockholders’ deficit of $30.4 million, leading management to state substantial doubt about the company’s ability to continue as a going concern. Nukkleus exited its financial services arm (DRFQ) and is repositioning toward the defense sector via an amended agreement to acquire 100% of Star 26 Capital. The company also raised $9.2 million net through a private placement and significantly increased its share count, while recording a $967,818 loss on 50 million DARWIN tokens whose fair value fell to $32,182.